Surgical robotics provider Stereotaxis' Q1 revenue misses analyst estimates

Stereotaxis

12/05/2026 21:17

Overview

Q1 revenue declined yr/yr, missing analyst expectations

Company posted Q1 net loss of $5.9 mln and EPS of -0.06

Revenue decline attributed to transition from legacy catheters and modest new product contributions

Outlook

Stereotaxis expects full-year 2026 revenue to surpass $40 mln

Company sees Q3 and Q4 2026 revenue each exceeding $10 mln

Stereotaxis expects to advance commercialization and achieve profitability without substantial investor dilution

Result Drivers

LEGACY PRODUCT TRANSITION - Recurring revenue pressured by transition away from dependency on legacy Johnson & Johnson catheters, with only modest contributions from new proprietary catheters

SUPPLY CONSTRAINTS - Demand for MAGiC catheter exceeds supply, with rollout in US and Europe limited by manufacturing ramp

PRODUCT ECOSYSTEM LAUNCHES - Regulatory approvals and new product introductions seen as foundational for future growth, but current revenue impact remains minor

Company press release: ID:nGNXMW21P

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$6.29 mln
$8.62 mln (5 Analysts)
Q1 EPS
-$0.06
Q1 Net Income
-$5.86 mln
Q1 Operating Expenses
$9.78 mln
Q1 Operating Income
-$5.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 112.8% above its May 11 closing price of $1.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)